Private company
Who owns Consolidated VIE (unnamed private medical device company developing therapies for advanced heart failure)
One company in the researched set discloses a stake in Consolidated VIE (unnamed private medical device company developing therapies for advanced heart failure), none of it sized by anyone who discloses it. Consolidated VIE (unnamed private medical device company developing therapies for advanced heart failure) is private, so no 13F reports it: a 13F covers exchange listed positions only. These figures exist because each holder disclosed the stake in its own filings.
What this is
A privately held medical technology company working on treatments for advanced heart failure, which Edwards Lifesciences consolidates as a variable interest entity after buying a majority equity stake and holding an option over the rest, and which Edwards deliberately leaves unnamed in the variable interest entity note of its own SEC filings, the only public record of it.
The disclosed stakes
One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.
Where each figure comes from
A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.
- Edwards Lifesciences Corporation. 10-Q Note 7, Business Combinations: on 22 May 2026 (the 'Consolidation Date') Edwards amended existing agreements with a private medical device company (the 'Consolidated VIE'), gaining the power to direct its significant activities (its regulatory process) and becoming its primary beneficiary under VIE accounting, so the entity is now consolidated in Edwards's financial statements even though Edwards holds only 'approximately 26.7% ownership of the Consolidated VIE's outstanding shares' (quoted directly from the filing). value_usd is null because the filing does not state a standalone value of Edwards's post-consolidation 26.7% equity stake. It gives instead: (a) the fair value of Edwards's PRE-consolidation investment (option $42.0m, notes $70.0m, preferred shares $56.6m, other $3.7m = $172.3m fair value of Edwards's investment held in the Consolidated VIE before the business combination), which mixes debt-like instruments (notes) with equity and is not the current value of the 26.7% stake; and (b) the fair value of the noncontrolling interest (the other ~73.3% of shares) at $112.4m. These two, $172.3m and $112.4m, sum to $284.7m total consideration used in purchase-price accounting, not a value of Edwards's equity percentage alone, so value_usd was left null rather than approximated from them. source
What this page is not
It is not a complete register. It lists the holders who happen to be inside the researched set and disclosed the stake themselves. A private company can have many other shareholders, and nothing here rules them out: venture investors, founders and employees usually appear in no public filing at all. Percentages are of Consolidated VIE (unnamed private medical device company developing therapies for advanced heart failure) where a holder stated one, and are missing where no holder did.